Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.

Thoracic cancer - 1 Mar 2026

Wu Lige, Zou Zihua, Li Yan, Hao Xuezhi, Zhang Jie, Ying Jianming, Xing Puyuan, Li Junling

Abstract excerpt

BACKGROUND: Chemoimmunotherapy is the first-line standard for advanced lung adenocarcinoma (LUAD) without driver mutations, but predictive biomarkers are still limited. TP53 is the most frequently mutated gene in LUAD, and its mutation subtypes affect treatment efficacy differently. METHODS: This is a retrospective observational study. We retrospectively analyzed 133 patients with advanced LUAD who received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CpG Islands

Share to Immunotherapy

Share to Lung Neoplasms

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41858121
DOI: 10.1111/1759-7714.70262
PMCID: PMC13097391

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.PMID 41858121Read ↗

Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.Semantic proximity Read ↗

Integration of multi-omics profiling reveals an epigenetic-based molecular classification of lung adenocarcinoma: implications for drug sensitivity and immunotherapy response predictionSemantic proximity Read ↗

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.Semantic proximity Read ↗

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burdenSemantic proximity Read ↗

Machine-learning-guided single-cell transcriptomic interrogation identifies biomarkers and candidate therapeutics for immune-cold lung adenocarcinomaSemantic proximity Read ↗

Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.Semantic proximity Read ↗

KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.Semantic proximity Read ↗

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.Semantic proximity Read ↗

Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.Semantic proximity Read ↗

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapySemantic proximity Read ↗

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.